Amgen Inc. (AMGN) Piper Sandler Digital Novel Targets in Immunology Symposium February 12, 2026 5:00 PM EST
Firm Individuals
Paul Burton – Senior VP & Chief Medical Officer
Casey Capparelli – Govt Director of Investor Relations
Convention Name Individuals
David Amsellem – Piper Sandler & Co., Analysis Division
Presentation
David Amsellem
Piper Sandler & Co., Analysis Division
All proper, everybody. Good afternoon. That is David Amsellem from the Piper Sandler Biopharma Analysis staff and a contented virtually Friday to everybody listening in. So within the subsequent 25 minutes, we’ll be talking with Amgen and plenty to speak about in the case of immunology and irritation. We’re delighted to have CMO, Paul Burton. We even have from the IR staff or the Head of the IR staff Casey Capparelli as nicely. Thanks, gents, for becoming a member of us.
Query-and-Reply Session
David Amsellem
Piper Sandler & Co., Analysis Division
So I do know there’s loads to speak about. And final week, there have been some new developments when it comes to new scientific trial initiations and in addition new knowledge. So I am admittedly going to bounce round. However one product I wished to begin with, Paul, in case you do not thoughts, is UPLIZNA. So clearly, you had the label expansions final yr. However you probably did focus on final week plans to provoke Part III research in autoimmune hepatitis and in addition persistent inflammatory demyelinating polyneuropathy later this yr. So I assume a high-level query right here. You bought a B-cell depleter in UPLIZNA. So perhaps speak about your rationale right here for transferring forward with these 2 scientific settings and assist us higher perceive the rationale for B-cell depletion in each of those scientific settings.
Paul Burton
Senior VP & Chief Medical Officer
Nice. David, look, thanks for having us. I feel as an organization, we have now sturdy expertise in B-cell depletion. We’ve got BLINCYTO which